Anti-CD38 Quadruplets Lead MRD Rankings; Transplant Benefit Remains Unproven
This network meta-analysis ranks 13 frontline strategies for measurable residual disease (MRD) negativity in newly diagnosed multiple myeloma and tests whether anti-CD38 antibodies improve its persistence, informing the quadruplet versus transplant debate.
📅 Journal publication: Nov 6, 2026·Last updated: Nov 16, 2026
Anti-CD38 regimens excel in achieving MRD negativity in myeloma.
The study evaluates the effectiveness of anti-CD38 monoclonal antibody-based regimens in newly diagnosed multiple myeloma. Anti-CD38-KRd regimens showed the highest MRD negativity, but adding ASCT did not significantly change outcomes. These findings suggest that anti-CD38 regimens are effective, but the role of ASCT may be limited. More data is needed for definitive conclusions. Anti-CD38-based treatments significantly improve MRD negativity in multiple myeloma.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Caridà G, Scalise L, Mosca A, De Fazio L, Costa M, Molica M, Rossi M
Citation:Caridà G, Scalise L, Mosca A, et al. Achievement and Persistence of MRD Negativity with Anti-CD38-Based Regimens in Newly Diagnosed Multiple Myeloma: A Systematic Review and Network Meta-Analysis. Cancers. 2026;18(21). doi:10.3390/cancers18213573